Cost-Effectiveness of Ceritinib In Previously Untreated ALK-Positive Non-Small Cell Lung Cancer in the United Kingdom
May 1, 2018, 00:00
10.1016/j.jval.2018.04.182
https://www.valueinhealthjournal.com/article/S1098-3015(18)30482-0/fulltext
Title :
Cost-Effectiveness of Ceritinib In Previously Untreated ALK-Positive Non-Small Cell Lung Cancer in the United Kingdom
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)30482-0&doi=10.1016/j.jval.2018.04.182
First page :
Section Title :
Open access? :
No
Section Order :
1033